Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282666 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRLMNAHSD11B1KDM4E | |
| SCHEMBL8889675 | 0.84 | TSHR (0.43) | SMN1; SMN2TSHRLMNAHSD11B1ALDH1A1 | |
| SCHEMBL31128665 | 0.84 | HCAR3 (0.44) | SMN1; SMN2TSHRHSD11B1KDM4EALDH1A1 | |
| SCHEMBL546932 | 0.68 | LMNA (0.59) | SMN1; SMN2TSHRLMNAALDH1A1CYP3A4 | |
| SCHEMBL9971714 | 0.68 | DHODH (0.36) | SMN1; SMN2TSHRLMNAHSD11B1ALDH1A1 | |
| SCHEMBL17192484 | 0.68 | CFTR (0.42) | SMN1; SMN2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL11079999 | 0.67 | MAOB (0.46) | LMNAHSD11B1MAOBCYP2D6AKR1C1 | |
| SCHEMBL11077137 | 0.67 | MAOB (0.46) | LMNAHSD11B1MAOBCYP2D6AKR1C1 | |
| SCHEMBL10651717 | 0.67 | MAOB (0.46) | LMNAHSD11B1MAOBCYP2D6AKR1C1 | |
| SCHEMBL18815073 | 0.67 | SIRT1 (0.39) | SMN1; SMN2TSHRHSD11B1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013008044-A1 | SYNTHESIS OF (+) AND (-) 1 -(5,5-DIPHENYLTETRAHYDROFURAN-3- YL)-N,N-DIMETHYLMETHANAMINE, (+) AND (-) 1-(2,2-DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHANAMINE AND (+) AND (-) 1-(2,2- DFFHENYLTETRAHYDROFURAN-3-YL)-N-METIHYLMETHANAMINE | ANAVEX LIFE SCIENCES CORP. (GR) | 2013-01-17 | — | — | WO | claimed |
| WO-1997030983-A1 | TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FERANEMETHANAMINE, ITS ENANTIOMERS, AND THEIR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS | VAMVAKIDES ALEXANDRE (GR) | 1997-08-28 | — | — | WO | claimed |
| US-12018005-B1 | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2024-06-25 | — | — | US | disclosed |
| US-12018005-B1 | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2024-06-25 | — | — | US | disclosed |
| WO-2013008044-A1 | SYNTHESIS OF (+) AND (-) 1 -(5,5-DIPHENYLTETRAHYDROFURAN-3- YL)-N,N-DIMETHYLMETHANAMINE, (+) AND (-) 1-(2,2-DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHANAMINE AND (+) AND (-) 1-(2,2- DFFHENYLTETRAHYDROFURAN-3-YL)-N-METIHYLMETHANAMINE | ANAVEX LIFE SCIENCES CORP. (GR) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013008044-A1 | SYNTHESIS OF (+) AND (-) 1 -(5,5-DIPHENYLTETRAHYDROFURAN-3- YL)-N,N-DIMETHYLMETHANAMINE, (+) AND (-) 1-(2,2-DIPHENYLTETRAHYDROFURAN-3-YL)-N,N- DIMETHYLMETHANAMINE AND (+) AND (-) 1-(2,2- DFFHENYLTETRAHYDROFURAN-3-YL)-N-METIHYLMETHANAMINE | ANAVEX LIFE SCIENCES CORP. (GR) | 2013-01-17 | — | — | WO | disclosed |
| WO-1997030983-A1 | TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FERANEMETHANAMINE, ITS ENANTIOMERS, AND THEIR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS | VAMVAKIDES ALEXANDRE (GR) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997030983-A1 | TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FERANEMETHANAMINE, ITS ENANTIOMERS, AND THEIR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS | VAMVAKIDES ALEXANDRE (GR) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018005-B1 | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form | PSEN2, PSEN1, APP | SMN1; SMN2 101/4885TSHR 4559/4885LMNA 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.